Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab + docetaxel followed by epirubicin + cyclophosphamide in HER2-positive operable breast cancer
2007-003466-18Phase 2Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Pathological complete response rate. Started Jul 2007; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003466-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003466-18.